We are live on ! Find out more
IRD

Opus Genetics
IRD

27 hedge funds and large institutions have $5.27M invested in Opus Genetics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,300% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 1

93% more funds holding

Funds holding: 14 → 27 (+13)

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

12.04% less ownership

Funds ownership: 20.38% → 8.35% (-12%)

64% less capital invested

Capital invested by funds: $14.5M → $5.27M (-$9.2M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
27
Holders Change
+13
Holders Change %
+92.86%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
14
Increased
4
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$1.11M
2
NPF
Norris Perne & French
Michigan
+$733K
3
PVI
Pura Vida Investments
New York
+$535K
4
Renaissance Technologies
Renaissance Technologies
New York
+$370K
5
BFM
Boothbay Fund Management
New York
+$124K

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$15.5M
2
Squarepoint
Squarepoint
New York
-$85.5K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$5.53K
4
APA
American Portfolios Advisors
New York
-$13
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Altium Capital Management
New York
$2.31M -$15.5M -1,671,494 -81%
IC
2
Ikarian Capital
Texas
$693K +$1.11M +119,551 New
Renaissance Technologies
3
Renaissance Technologies
New York
$660K +$370K +39,800 +54%
NPF
4
Norris Perne & French
Michigan
$458K +$733K +78,909 New
PVI
5
Pura Vida Investments
New York
$334K +$535K +57,536 New
Comerica Bank
6
Comerica Bank
Texas
$143K – – –
RCM
7
Regency Capital Management
Hawaii
$99K +$158K +17,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$79K -$5.53K -595 -4%
BFM
9
Boothbay Fund Management
New York
$78K +$124K +13,389 New
Millennium Management
10
Millennium Management
New York
$74K +$118K +12,692 New
SFO
11
Stokes Family Office
Louisiana
$70K +$113K +12,120 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$65K +$105K +11,300 New
Squarepoint
13
Squarepoint
New York
$60K -$85.5K -9,207 -47%
MA
14
MCF Advisors
Kentucky
$55K +$88.3K +9,499 New
Morgan Stanley
15
Morgan Stanley
New York
$36K +$50.7K +5,456 +779%
TRCT
16
Tower Research Capital (TRC)
New York
$15K +$19.3K +2,081 +466%
BlackRock
17
BlackRock
New York
$13K – – –
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$13K +$20.2K +2,174 New
UBS Group
19
UBS Group
Switzerland
$11K +$16.8K +1,810 New
First Manhattan
20
First Manhattan
New York
$3K +$5.58K +600 New
SPIA
21
Steward Partners Investment Advisory
New York
$87 +$139 +15 New
APA
22
American Portfolios Advisors
New York
– -$13 -2 Closed
Osaic Holdings
23
Osaic Holdings
Arizona
– +$37 +4 +24%
CAM
24
Close Asset Management
United Kingdom
– +$186 +20 New

IRD Hedge Fund Activity: Q1 2021 in Review

27 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2021, worth a combined $5.27M — down 64% from $14.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IRD positions and 1 closed out — a net gain of 13 holders — while 4 added to existing stakes and 3 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.11M. The largest seller was Altium Capital Management, cutting an estimated $15.5M.

  • 27 institutional investors held Opus Genetics (IRD) as of Q1 2021, up from 14 in Q4 2020.
  • Funds reported $5.27M of Opus Genetics stock for Q1 2021, down 64% quarter-over-quarter.
  • 14 funds opened new Opus Genetics positions in Q1 2021 and 1 closed out, a net change of +13 holders.
  • The largest Opus Genetics buyer in Q1 2021 was Ikarian Capital, an estimated $1.11M added.
  • The largest Opus Genetics seller in Q1 2021 was Altium Capital Management, an estimated $15.5M sold.

Based on aggregated 13F filings for Q1 2021.